Editorial Comment

Imaging has demonstrated growing usefulness for the detection of prostate cancer. Previous data have shown that MRI fusion biopsy improves the identification of clinically significant prostate cancer and reduces the detection of clinically insignificant cancer compared to standard TRUS guided biopsy.1 In this article Simmons et al found that MRI targeted biopsy diagnosed 81% of cases of clinically significant cancer while reducing the diagnosis of clinically insignificant disease by 40% compared to saturation transperineal template biopsy sampling in men in the PICTURE trial requiring repeat biopsy.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Adult Urology Source Type: research